Table 2.
Factors associated with the risk of being lost to follow up between Month-6 and Month-18 in patients in care at Month-6, CePReF HIV care center, Abidjan, Côte d’Ivoire
| Univariate |
Multivariate |
|||||
|---|---|---|---|---|---|---|
| HR | (95% CI) |
p- value |
AHR | (95% CI) |
p- value |
|
| Sex (men vs. women) | 1.12 | (0.78–1.60) | 0.54 | - | - | - |
| Age in years (≤35 vs. ≥35) | 1.39 | (1.01–1.93) | 0.04 | 1.29 | (0.93–1.81) | 0.13 |
| Living outside the district (yes vs. no) | 1.44 | (1.04–1.99) | 0.03 | 1.53 | (1.10–2.13) | 0.01 |
| Pre-ART body mass index (<19.5 vs. ≥ 19.5 kg/m2) | 1.08 | (0.78–1.49) | 0.64 | - | - | - |
| Pre-ART CD4 count | 0.06 | 0.06 | ||||
| < 100 vs. ≥ 200/mm3 | 0.95 | (0.63–1.44) | 0.82 | 1.02 | (0.67–1.55) | 0.91 |
| 100–199 vs. ≥ 200/mm3 | 1.46 | (0.99–2.16) | 0.06 | 1.53 | (1.03–2.27) | 0.04 |
| First ART regimen (PI-based vs. others) | 1.55 | (0.76–3.17) | 0.22 | - | - | |
| M0-M6 Medication Possession Ratio | 0.0001 | 0.0001 | ||||
| <50 vs. ≥95% | 6.96 | (4.45–10.88) | 0.0001 | 5.74 | (3.60–9.15) | 0.0001 |
| 50–79 vs. ≥95% | 4.16 | (2.73–6.33) | 0.0001 | 4.02 | (2.62–6.16) | 0.0001 |
| 80–94 vs. ≥95% | 1.38 | (0.86–2.22) | 0.18 | 1.46 | (0.90–2.35) | 0.13 |
| Type of follow-up (enhanced vs. routine) | 0.48 | (0.33–0.70) | 0.0001 | 0.54 | (0.37–0.78) | 0.001 |
HR: Hazard Ratio; AHR: adjusted Hazard Ratio; CI: Confidence interval; PI: Protease inhibitor
M0-M6 Medication Possession Ratio: number of daily doses of antiretroviraldrug provided divided by total number of follow-up days since ART initiation